Discovering New Genetic Markers in Adults and Children Who May Be At Risk for Hereditary Forms of Cancer

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Apr 18, 2019

Keywords

ClinConnect Summary

This clinical trial is focused on finding new genetic markers that may indicate a higher risk for hereditary cancers in both adults and children. By identifying specific genetic changes, the researchers hope to help individuals understand their cancer risk better, which could lead to earlier treatment or even ways to reduce that risk. The study is currently looking for participants, and anyone who has had genetic testing or has a family history of cancer may be eligible to join. This includes people who have had cancer themselves, as well as family members of those who meet the criteria.

If you decide to participate, you will undergo evaluations to see if you have any genetic markers associated with cancer risk. The study welcomes individuals from all age groups, including children with parental consent. It's important to note that people with certain physical or mental health conditions that make it hard to understand the study may not be able to participate. Overall, this trial aims to provide valuable insights into hereditary cancer risks and improve future prevention and treatment strategies.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Individuals who have undergone clinical and/or research genetic evaluation, found to have or not have a germline genetic variant (pathogenic, likely pathogenic, variant of uncertain/unknown significance, likely benign).
• • Individuals with or without a personal history of malignant or pre-malignant lesions who demonstrate: a) clinical findings suggestive of a genetic cancer susceptibility syndrome including very early age at onset, multiple primary malignancies, or other features; and/or b) family histories suggestive of a genetic cancer susceptibility syndrome, or c) other features suggesting inherited etiology of malignancy as determined by the PI.
• • Family members of the above participants. Both children (with parental consent as age appropriate) and adults are eligible to participation.
• • Individuals may or may not be enrolled MSK patients; probands may be referred to (or self-referred to) the study and may be enrolled at discretion of the PI and if able to provide informed consent.
• • Biospecimens derived from deceased family members may be used for research in this study if consent if provided by the executor of the estate of that individual.
• Exclusion Criteria:
• • Patients will be excluded from this study if he/she has physical, cognitive or psychiatric conditions that interfere with ability to give meaningful informed consent.